According to Xinhua Medical's announcement, the company and its wholly-owned subsidiary Shandong Xinhua Blood Technology Co., Ltd. recently received the “People's Republic of China Medical Device Registration Certificate” issued by the State Drug Administration and the Shandong Drug Administration. Among them, hemodialysis devices are suitable for hemodialysis treatment for patients with acute and chronic renal failure. The approval date is December 23, 2025, and the validity period is until December 22, 2030. Products such as procalcitonin test kits and serum amyloid A/C-reactive protein dual test kits have also obtained corresponding registration certificates.

According to Xinhua Medical's announcement, the company and its wholly-owned subsidiary Shandong Xinhua Blood Technology Co., Ltd. recently received the “People's Republic of China Medical Device Registration Certificate” issued by the State Drug Administration and the Shandong Drug Administration. Among them, hemodialysis devices are suitable for hemodialysis treatment for patients with acute and chronic renal failure. The approval date is December 23, 2025, and the validity period is until December 22, 2030. Products such as procalcitonin test kits and serum amyloid A/C-reactive protein dual test kits have also obtained corresponding registration certificates.